Analyzing prostate-specific antigen (PSA) velocity and its rate of increase over time may help physicians better assess which patients require biopsy and active treatment and could, according to researchers from Innsbruck, Austria, result in significant healthcare savings. These data were presented during the 105th Annual Meeting of the American Urological Association (AUA). The session was moderated by William J. Catalona, MD, an expert in prostate cancer and PSA. "We have made exciting discoveries since the abstract was submitted," said Jasmin Bektic, MD, who presented the data...
More...
More...